Experimental cognition-related small molecule · Fact sheet
Sunifiram
Also known as DM235
Sunifiram is an experimental small molecule with rodent and laboratory cognition studies. Human efficacy, pharmacokinetics and a safe treatment regimen are not established.
What is Sunifiram?
Sunifiram is a piperazine derivative often discussed alongside racetams, but it is a distinct chemical family.
Preclinical AMPA- and NMDA-related observations do not establish a complete or selective human mechanism.
Benefits & claims
Readers encounter Sunifiram in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.
What the evidence supports
- Rodent experiments found effects on selected memory tasks and excitatory signaling.
- Laboratory synaptic efficacy is a surrogate, not everyday learning or a human disease outcome.
- A potent animal result does not supply a defensible human dose or frequency.
Research areas
- Cognition and memory
- Neurologic or psychiatric research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Sunifiram. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Sunifiram is a piperazine derivative often discussed alongside racetams, but it is a distinct chemical family.
Formulation differences
- Preclinical AMPA- and NMDA-related observations do not establish a complete or selective human mechanism.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Side effects & risks
- Effects of changing excitatory neurotransmission require direct neurologic safety evaluation.
- Human toxicity thresholds, seizure liability, interactions and repeated-exposure risks remain unknown rather than proven absent.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe cited evidence is preclinical, including induced-amnesia models and hippocampal physiology.
Studies
Original preclinical DM235 cognitive experiments.
AMPA-related animal experiments with sunifiram and unifiram.
Preclinical hippocampal synaptic-efficacy study.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Sunifiram is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer.
- AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).
- Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.
Open questions
- Reproducible benefit on everyday function in the intended population
- Long-term safety and clinically important interactions
- Equivalence of nonstandard products to research formulations
Summary
A potent animal result does not supply a defensible human dose or frequency.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedDM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer.
Original preclinical DM235 cognitive experiments.
- pubmedAMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).
AMPA-related animal experiments with sunifiram and unifiram.
- pubmedNovel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.
Preclinical hippocampal synaptic-efficacy study.